SCHEMBL83965

SCHEMBL83965

CN1C(=O)CNCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4929861 0.97 BRPF1 (0.39)
SCHEMBL2916410 0.82 BRPF1 (0.34)
SCHEMBL7945735 0.76
SCHEMBL23894741 0.76 GSK3A (0.38)
SCHEMBL26831156 0.75
SCHEMBL377630 0.73
SCHEMBL2945673 0.72 BRPF1 (0.56)
SCHEMBL23153195 0.71 GSK3A (0.35)
SCHEMBL2051344 0.71
SCHEMBL18058915 0.71 CASP3 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US claimed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 EP claimed
US-20230331760-A1 ARYL GLUCOSIDE DERIVATIVE AND USE THEREOF IN DRUG SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) 2023-10-19 US disclosed
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230146675-A1 PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-05-11 US disclosed
CN-115996927-A Pyrimido [5,4-d ] pyrimidine derivatives and combinations with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer ITEOS比利时公司 2023-04-21 CN disclosed
EP-4110784-A1 PYRIMIDO[5,4-D]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-01-04 EP disclosed
US-9669095-B2 Cyclosporin analogues for preventing or treating hepatitis C infection ENANTA PHARMACEUTICALS, INC. (US) 2017-06-06 US disclosed
US-20170049781-A1 HSP90 INHIBITOR COMBINATIONS NOVARTIS AG (CH) 2017-02-23 US disclosed
US-20170049781-A1 HSP90 INHIBITOR COMBINATIONS NOVARTIS AG (CH) 2017-02-23 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed
EP-1025095-A1 SUBSTITUTED CHROMAN DERIVATIVES AstraZeneca AB (SE) 2000-08-09 EP disclosed
WO-1999014212-A1 SUBSTITUTED CHROMAN DERIVATIVES ASTRAZENECA AB (SE) 1999-03-25 WO disclosed
EP-0197241-B1 PIPERAZIN-1-YL-ERGOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FARMITALIA CARLO ERBA S.r.l. (IT) 1989-12-27 EP disclosed
US-4728649-A HYPOTENSIVE, ANXIOLYTIC, NEUROLEPTIC FARMITALIA CARLO ERBA (IT) 1988-03-01 US disclosed
EP-0197241-A1 Piperazin-1-yl-ergoline derivatives, process for preparing them and pharmaceutical compositions containing them FARMITALIA CARLO ERBA S.r.l. (IT) 1986-10-15 EP disclosed
EP-0154190-A1 Pyridones MERCK PATENT GmbH (DE) 1985-09-11 EP disclosed